Cargando…
Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy
Mechanisms of cardiomyopathy caused by obesity/hyperlipidemia are complicated. Obesity is usually associated with chronic low-grade inflammation and may lead to the onset and progression of myocardial fibrosis and remodeling. TLR4/MyD88 signaling pathway, as a key regulator of inflammation, plays an...
Autores principales: | Zheng, Xu-yong, Sun, Chu-chu, Liu, Qian, Lu, Xiao-yao, Fu, Li-li, Liang, Guang, Zhang, Xiu-hua, Chen, Gao-zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468329/ https://www.ncbi.nlm.nih.gov/pubmed/32341464 http://dx.doi.org/10.1038/s41401-020-0410-x |
Ejemplares similares
-
Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
por: Luo, Wu, et al.
Publicado: (2022) -
MyD88 deficiency aggravates the severity of acute pancreatitis by promoting MyD88-independent TRIF pathway-mediated necrosis
por: Yang, Du-Jiang, et al.
Publicado: (2022) -
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
por: Saikh, Kamal U.
Publicado: (2021) -
Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis
por: Zheng, Chao, et al.
Publicado: (2020) -
A MyD88 meddles with survival
por: Bashyam, Hema
Publicado: (2007)